Arkolith/Insider Trading/OYST/Form 4

Snisarenko John

Chief Commercial OfficerOyster Point Pharma, Inc. (OYST) · full profile →Form 4 · filed Jan 11, 2022
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 9, 2022Grant(A)12K—$030K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 9, 2022Grant(A)55K—$055K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-22-002980) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML